Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Price Not Available 10mg Rebastinib (DCC-2036) Supplier Page

Trivial name	N/A
Catalog Number	S2634
Molecular Formula	C17H16N2O3
CAS#	1020172-07-9
Inchi	InChI=1S/C17H16N2O3/c1-10-9-18-15(11(10)6-7-16(20)21)8-13-12-4-2-3-5-14(12)19-17(13)22/h2-5,8-9,18H,6-7H2,1H3,(H,19,22)(H,20,21)/b13-8-
Inchi Key	JNDVEAXZWJIOKB-JYRVWZFOSA-N
SMILES	CC1=CNC(=C1CCC(=O)O)C=C2C3=CC=CC=C3NC2=O
Size	10mg
Supplier Page	http://www.selleckchem.com/products/dcc-2036.html
Additional Information	https://file.selleck.cn/downloads/struct/DCC-2036-chemical-structure-s2634.gif